Clinical trials: Active Psoriatic Arthritis
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and…
- Conditions
- Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
- Trial name
- NCT03357471
- Testing
- e-Device
- Where
- 22 sites in United States
- Volunteers
- 70 people
- Sponsor
- UCB Biopharma S.P.R.L.
Psoriatic Arthritis
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
- Trial name
- NCT02798211
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 58 sites in United States, Puerto Rico
- Volunteers
- 258 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the…
- Trial name
- COSMOS (NCT03796858)
- Testing
- Guselkumab 100 mg
- Where
- 117 sites in Belgium, Bulgaria and 12 more
- Volunteers
- 285 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Psoriatic Arthritis
A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197
A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT).
- Trial name
- NCT02429895
- Testing
- ABT-122
- Where
- 36 sites in Australia, Bulgaria and 8 more
- Volunteers
- 168 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis…
- Trial name
- PENGUIN 2 (NCT04115839)
- Testing
- Filgotinib
- Where
- 59 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Psoriatic Arthritis
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
- Trial name
- NCT05511519
- Testing
- ATI-450
- Where
- 22 sites in United States, Poland
- Volunteers
- 47 people
- Sponsor
- Aclaris Therapeutics, Inc.
Psoriatic Arthritis
Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])
A special investigation (post marketing observational study [PMOS]/non-mandatory) of HUMIRA® in Japanese psoriatic arthritis patients who are engaged in paid work.
- Trial name
- NCT02414633
- Volunteers
- 148 people
- Sponsor
- AbbVie
Arthritis, Psoriatic
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and…
- Trial name
- NCT01490450
- Testing
- BMS-945429
- Where
- 49 sites in United States, Argentina and 11 more
- Volunteers
- 165 people
- Sponsor
- CSL Behring
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are…
- Trial name
- EXCEED 1 (NCT02745080)
- Testing
- Secukinumab, Adalimumab
- Where
- 156 sites in United States, Australia and 24 more
- Volunteers
- 853 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen…
- Trial name
- PALACE-1 (NCT01172938)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 504 people
- Sponsor
- Amgen
Psoriatic Arthritis
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.
- Trial name
- NCT01925768
- Testing
- Apremilast 30 mg
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 219 people
- Sponsor
- Amgen
Active Psoriatic Arthritis
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.
- Trial name
- NCT03881059
- Testing
- BMS-986165 Dose A, BMS-986165 Dose B, Ustekinumab
- Where
- 94 sites in United States, Czechia and 7 more
- Volunteers
- 203 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, and up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous…
- Trial name
- NCT01989468
- Testing
- Secukinumab
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 414 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Idiopathic Arthritis
Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis
This is a multicenter, non-interventional, cohort study in pediatric patients with active juvenile enthesitis-related or psoriatic arthritis
- Trial name
- Toddler (NCT06431750)
- Testing
- Secukinumab
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to…
- Trial name
- SELECT - PsA 1 (NCT03104400)
- Testing
- Adalimumab, Upadacitinib
- Where
- 345 sites in United States, Argentina and 44 more
- Volunteers
- 1,705 people
- Sponsor
- AbbVie
Psoriatic Arthritis
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
- Trial name
- BE VITAL (NCT04009499)
- Testing
- Bimekizumab
- Where
- 138 sites in United States, Australia and 12 more
- Volunteers
- 1,131 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after…
- Trial name
- NCT04109976
- Testing
- Bimekizumab
- Where
- 47 sites in United States, Czechia and 4 more
- Volunteers
- 214 people
- Sponsor
- UCB Biopharma SRL
Arthritis, Psoriatic
A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis
This study is open to adults with active psoriatic arthritis who have tender and swollen joints. The purpose of this study is to find out whether a medicine called BI 730357 helps to reduce symptoms and to prevent damage to…
- Trial name
- NCT04680676
- Testing
- BI 730357
- Sponsor
- Boehringer Ingelheim
Active Psoriatic Arthritis
Efficacy and Safety Study of SUNPG1623
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
- Trial name
- NCT02980692
- Testing
- SUNPG1623 I, SUNPG1623 II, SUNPG1623 III
- Where
- United States
- Volunteers
- 391 people
- Sponsor
- Sun Pharmaceutical Industries Limited